Latest filing published 04 Sept 2026 for Krystal Biotech, Inc., €981k.
First 200 filings with a declared amount
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
At Krystal Biotech, Inc., Suma Krishnan, President, R&D, appears in 248 filings, including 210 sales and 5 purchases; 2 filings concern Precigen, Inc. The sales weigh EUR 112.0 million with a median of EUR 360,423, the purchases EUR 1,507,886 with a median of EUR 124,088 (2% of market trades). The largest sale, EUR 6,242,634, goes back to December 10, 2021. Two others, EUR 2,184,252 and EUR 2,048,159, took place on May 31, 2023. The largest purchases are dated September 22, 2017 (EUR 837,130), October 18, 2018 (EUR 436,300) and June 6, 2018 (EUR 124,088).
Across 250 filings there are also 18 share grants, 14 option exercises and 3 filings of another kind. The peak is 2024 with 67 filings, ahead of 2025 (53) and 2023 (44), while 2021 has only 2. In all, 50 filings, 39 of them sales, fall in the last twelve months.
Krish S. Krishnan is the closest colleague, with 204 trades within 30 days of Suma Krishnan's. Next come Kathryn Romano (40), Daniel Janney (25), Dino A. Rossi (23) and Julian S. Gangolli (16), in the same direction. Filings are published a median of 1 day after the trade.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 250 declarations